These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9222089)

  • 41. Histopathological and ophthalmoscopic evaluation of apocynin on experimental proliferative vitreoretinopathy in rabbit eyes.
    Ozer MA; Polat N; Ozen S; Ogurel T; Parlakpinar H; Vardi N
    Int Ophthalmol; 2017 Jun; 37(3):599-605. PubMed ID: 27495951
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial.
    Ahmadieh H; Feghhi M; Tabatabaei H; Shoeibi N; Ramezani A; Mohebbi MR
    Ophthalmology; 2008 Nov; 115(11):1938-43. PubMed ID: 18584876
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy.
    Cardillo JA; Farah ME; Mitre J; Morales PH; Costa RA; Melo LA; Kuppermann B; Jorge R; Ashton P
    Br J Ophthalmol; 2004 Sep; 88(9):1201-5. PubMed ID: 15317716
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy.
    Andrews A; Balciunaite E; Leong FL; Tallquist M; Soriano P; Refojo M; Kazlauskas A
    Invest Ophthalmol Vis Sci; 1999 Oct; 40(11):2683-9. PubMed ID: 10509666
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Slow-Release Dexamethasone in Proliferative Vitreoretinopathy: A Prospective, Randomized Controlled Clinical Trial.
    Banerjee PJ; Quartilho A; Bunce C; Xing W; Zvobgo TM; Harris N; Charteris DG
    Ophthalmology; 2017 Jun; 124(6):757-767. PubMed ID: 28237428
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of retinoic acid on retinal pigment epithelium from excised membranes from proliferative vitreoretinopathy.
    Wu WC; Hu DN; Mehta S; Chang YC
    J Ocul Pharmacol Ther; 2005 Feb; 21(1):44-54. PubMed ID: 15718827
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The significance of fibroblasts in experimental modeling of proliferative vitreoretinopathy].
    Khoroshilova-Maslova IP; Leparskaya NL; Vorotelyak EA; Vasiliev AV
    Vestn Oftalmol; 2017; 133(5):4-10. PubMed ID: 29165406
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy.
    Ozerdem U; Mach-Hofacre B; Cheng L; Chaidhawangul S; Keefe K; McDermott CD; Bergeron-Lynn G; Appelt K; Freeman WR
    Curr Eye Res; 2000 Jun; 20(6):447-53. PubMed ID: 10980656
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IL-10 in vivo gene expression in a cell-induced animal model of proliferative vitreoretinopathy.
    Bali E; Willermain F; Caspers-Velu L; Dubois C; Dehou MF; Velu T; Libert J; Bruyns C
    Int J Mol Med; 2003 Sep; 12(3):305-10. PubMed ID: 12883645
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor.
    Ikuno Y; Kazlauskas A
    Invest Ophthalmol Vis Sci; 2002 Jul; 43(7):2406-11. PubMed ID: 12091444
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravitreal and subretinal proliferation induced by platelet-rich plasma injection in rabbits.
    Piñon RM; Pastor JC; Saornil MA; Goldaracena MB; Layana AG; Gayoso MJ; Guisasola J
    Curr Eye Res; 1992 Nov; 11(11):1047-55. PubMed ID: 1483335
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of Serial Intrasilicone Oil Bevacizumab Injections in Eyes With Recurrent Proliferative Vitreoretinopathy Retinal Detachment.
    Hsu J; Khan MA; Shieh WS; Chiang A; Maguire JI; Park CH; Garg SJ; Ho AC; Kaiser RS
    Am J Ophthalmol; 2016 Jan; 161():65-70.e1-2. PubMed ID: 26432568
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Evaluation of experimental proliferative vitreoretinopathy in rabbits].
    Kuriyama S; Ohuchi T; Okada M; Yamakawa R; Yoshimura N; Honda Y
    Nippon Ganka Gakkai Zasshi; 1990 Sep; 94(9):792-8. PubMed ID: 2248164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intraocular injection of silicone oil for experimental proliferative vitreoretinopathy.
    Fastenberg DM; Diddie KR; Delmage JM; Dorey K
    Am J Ophthalmol; 1983 May; 95(5):663-7. PubMed ID: 6846457
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Proliferative vitreoretinopathy: prophylactic treatment].
    Chiquet C; Rouberol F
    J Fr Ophtalmol; 2014 Nov; 37(9):737-43. PubMed ID: 25012973
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Vitrectomy in proliferative vitreoretinopathy. Anatomical and functional results in 501 patients].
    Körner F; Böhnke M
    Klin Monbl Augenheilkd; 1995 Apr; 206(4):239-45. PubMed ID: 7791283
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Role of Chlamydia trachomatis intraocular infection in the development of proliferative vitreoretinopathy (experimental study)].
    Boiko EV; Pozniak AL; Suetov AA; Mal'tsev DS; Nuralova IV
    Vestn Oftalmol; 2015; 131(1):50-57. PubMed ID: 25872387
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Repeated Injection of Methotrexate into Silicone Oil-Filled Eyes for Grade C Proliferative Vitreoretinopathy: A Pilot Study.
    Nourinia R; Borna F; Rahimi A; Jabbarpoor Bonyadi MH; Amizadeh Y; Daneshtalab A; Kheiri B; Ahmadieh H
    Ophthalmologica; 2019; 242(2):113-117. PubMed ID: 31163427
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Morphological changes in the ocular structures in the simulation of proliferative vitreoretinopathy and in the presence of an extraocular focus of chronic infection].
    Boĭko EV; Shishkin MM; Riabous EA; Lepneva SV
    Vestn Oftalmol; 2010; 126(4):25-30. PubMed ID: 20873154
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Restoration of retinoic acid concentration suppresses ethanol-enhanced c-Jun expression and hepatocyte proliferation in rat liver.
    Chung J; Liu C; Smith DE; Seitz HK; Russell RM; Wang XD
    Carcinogenesis; 2001 Aug; 22(8):1213-9. PubMed ID: 11470752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.